Ideal Implant Incorporated announces the release of its ten-year FDA Core Clinical Trial Data, indicating that the Structured Implant presents a substantially lower risk of two major breast implant complications compared to the silicone gel implants.

While silicone gel implants have dominated the industry since they were allowed back on the market in 2006, technological advances over the past decade are now eliminating the need for accepting certain risks associated with silicone gel.

Read the full article at